The results revealed that the mRNA expression of PPT2 has no significant correlations with patients' age and gender (Figure 2B-C), while lower PPT2 mRNA expression was associated with worse M stage, survival status, T stage, pathological grades and TNM stage in ccRCC patients (Figure 2D-H). This evidence concerns the gene PPT2 and nonpapillary renal cell carcinoma.